Ovarian Cancer Care Shifts Toward Personalised Treatment

Ovarian cancer treatment is becoming increasingly personalised, with oncologists citing robotic surgery, targeted maintenance therapies and antibody-drug conjugates as key advances. Molecular testing now guides care, identifying patients with BRCA mutations or HRD who may benefit from PARP inhibitors such as olaparib, niraparib and rucaparib. Doctors say treatment decisions increasingly reflect each patient's tumour biology and genetic profile.